Abstract:Objective To evaluate initial outcome and summarize the clinical experience of prostate cancer treat by CyberKnife. Methods From May.2012 to Sept.2013, 34 prostate cancer patients were treated with radiotherapy by the fourth generation Cyberknife system （ stereotactic radiosurgery platform ） . The mean age of patients was 73.4 （54-84） years.24 cases initially treated with radical radiotherapy were combined with hormonal therapy （group A）, 5 cases were initially treated with radical radiotherapy （group B） , 5 cases with clinically localized prostate cancer and PSA rising during the hormonal therapy or entered CRPC stage were treated by Cyberknife （group C）.5 of the 24 cases and 1 of the 5 cases with clinically lo-calized prostate cancer with PSA rises during the hormonal therapy or entered CRPC stage treat by Cy -berknife received pelvic radiotherapy before the treatment. The median PSA before radiotherapy was 17.74 （0.20-100.00） μg/L.The median PSA of group A before radiotherapy was 19.80（6.60-100.00） μg/L. The median PSA of group B before radiotherapy was 12.50（ 9.43-75.50） μg/L.The median PSA of group C before radiotherapy was 0.67 （0.20-15.08） μg/L.6 cases of Gleason ≤6, 13 cases of Gleason=7, 12 ca-ses of Gleason≥8, three patients failed to get the Gleason score before the treatment .Four gold fiducials were implanted into prostate guided by transrectal ultrasound 1 week before the radiotherapy .A total dose of 36.25-37.50 Gy delivered in five fractions. Results The PSA of 33 cases decreased significantly at 1, 3 and 6 months after the treatment , and the median PSA were 0.83 , 0.10 and 0.07μg/L.One case′s PSA did not decrease.The median PSA of the group A at 1, 3 and 6 months were 0.14, 0.05 and 0.02 μg/L.The effects of radiation needed to be evaluated when the hormonal therapy ended .The median PSA of the group B at 1, 3 and 6 months were 6.35, 4.30, and 1.20μg/L.The median PSA of group C at 1, 3 and 6 months were 0.28, 0.22 and 0.13μg/L.2 cases had dysuria , mild hematuria during the treatment .1 case had mild rectal bleeding during treatment .C onclusions The therapeutic effect of radiotherapy for prostate cancer de-livered by CyberKnife is excellent .Its long-term efficacy and safety need to be further evaluated . Key words: Cyberknife; Prostate cancer; Radiotherapy; Hormonal therapy; Castration re-sistant prostate cancer

Clinical Analysis of Cyberknife Radiosurgery in the Treatment of 26 Patients with Adrenal Gland Neoplasms

Treating Adrenal Tumors In 26 Patients With Cyberknife: A Mono-Institutional Experience

Clinical Efficacy of CyberKnife Radiosurgery in Treatment of Adrenal Metastases: a Study of 42 Patients

Clinical Analysis of Cyberknife Stereotactic Surgery for Lung Tumors

Clinical analysis of 35 patients with liver tumor treated by cyberknife

Clinical efficacy of Stereotactic Body Radiation Therapy (SBRT) for adrenal gland metastases: A multi-center retrospective study from China

Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases.

Clinical outcomes of CyberKnife radiosurgery for patients with peripheral stage Ⅰ non-small cell Lung cancer

Clinical Observation on the Therapeutic Efficacy of Cyberknife for Primary or Metastastic Retroperitoneal Tumors

Effect and Safety of Robotic Radiosurgery in the Treatment of 42 Patients with Adrenal Metastases

Preliminary results for patients with early peripheral non-small cell lung cancer treated by Cyberknife

Robotic Stereotactic Irradiation and Reirradiation for Spinal Metastases: Safety and Efficacy Assessment.

Clinical observation on Cyberknife radiosurgery radiotherapy combined with EGFR-TKI in the treatment of 24 patients with advanced non-small cell lung cancer

Analysis of Clinical Efficacy of CyberKnife(®) Treatment for Locally Advanced Pancreatic Cancer.

Clinical Analysis of Stereotactic Body Radiation Therapy Using Extracranial Gamma Knife for Patients with Mainly Bulky Inoperable Early Stage Non-Small Cell Lung Carcinoma

Clinical experience of C yberknife radiotherapy for prso tate canec r

Clinical experience of Cyberknife radiotherapy for prostate cancer

Clinical Outcomes of CyberKnife Stereotactic Body Radiotherapy for Peripheral Stage I Non-Small Cell Lung Cancer

Clinical Efficacy of CyberKnife Radiotherapy for Locally Advanced Pancreatic Carcinoma

Stereotactic Body Radiotherapy Using CyberKnife for Locally Advanced Unresectable and Metastatic Pancreatic Cancer

Results and prognostic factors of CyberKnife for lung metastasis